About us
The OxCAn Story
The OxCAn Story
Oxford Cancer Analytics was formed in 2018 and won the 2019 Oxford University All-Innovate competition. The founders came together with a single goal - to save lives. DEcancer.AI relies only on the biomarkers found in a standard blood test, known as a liquid biopsy to diagnose patients with lung cancer at an earlier stage than is typical for conventional methods. This product would have the potential to save patients money, protect them from the painful invasive testing and harmful radiation, and detect lung cancer while it can still be treated.
Oxford Cancer Analytics was formed in 2018 and won the 2019 Oxford University All-Innovate competition. The founders came together with a single goal - to save lives. DEcancer.AI relies only on the biomarkers found in a standard blood test, known as a liquid biopsy to diagnose patients with lung cancer at an earlier stage than is typical for conventional methods. This product would have the potential to save patients money, protect them from the painful invasive testing and harmful radiation, and detect lung cancer while it can still be treated.
The team has since shown no signs of slowing, and has developed a prototype tool for detecting lung cancer. Because they understand that a missed diagnosis is unacceptable, they have broken away from the industry standard to give patients the best chance to discover their cancer before it is too late. To learn more, meet the team or get in touch.
The team has since shown no signs of slowing, and has developed a prototype tool for detecting lung cancer. Because they understand that a missed diagnosis is unacceptable, they have broken away from the industry standard to give patients the best chance to discover their cancer before it is too late. To learn more, meet the team or get in touch.
